Neogen (FRA:NG2) Total Equity: €1,778.6 Mil (As of Feb. 2026)


FRA:NG2 Neogen Corp FRA:NG2
68 GF Score
Price €8.40
GF Value €10.73
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Neogen Total Equity?

Neogen FRA:NG2 +5.08% 68 Total Equity is €1,778.6 Mil as of Feb. 2026. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €10.73 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Neogen's total equity for the quarter that ended in Feb. 2026 was €1,778.6 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Neogen Total Equity Historical Data

* Premium members only.

The historical data trend for Neogen's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neogen Total Equity Chart

Neogen Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 691.63 839.46 2,883.48 2,908.33 1,837.20

Neogen Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,553.93 1,837.20 1,819.92 1,820.38 1,778.63
FRA:NG2
68GF Score
Neogen Corp FRA:NG2
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neogen Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Neogen's Total Equity for the fiscal year that ended in May. 2025 is calculated as

Total Equity=Total Assets(Q: May. 2025 )-Total Liabilities(Q: May. 2025 )
=3054.683-1217.48
=1,837.2

Neogen's Total Equity for the quarter that ended in Feb. 2026 is calculated as

Total Equity=Total Assets(Q: Feb. 2026 )-Total Liabilities(Q: Feb. 2026 )
=2841.714-1063.084
=1,778.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1,778.6 Mil mean?
Neogen (FRA:NG2) has a Total Equity of €1,778.6 Mil as of Feb. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Neogen and its competitors.
Is Neogen's Total Equity too high?
Neogen's current Total Equity is €1,778.6 Mil. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Total Equity compare to UFPT and ALMR?
Neogen's Total Equity of €1,778.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Neogen and its competitors. Neogen's current Total Equity is €1,778.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.73, compared to a current price of €8.40 — trading 21.8% below its estimated fair value. The current Total Equity is €1,778.6 Mil. Neogen's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Total Equity is €1,778.6 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neogen (FRA:NG2) Overvalued in 2026?

Based on GuruFocus' analysis, Neogen stock appears to be undervalued. The current stock price of €8.40 is trading 21.8% below its estimated GF Value™ of €10.73. GuruFocus considers Neogen to be Modestly Undervalued.

Key valuation signals for FRA:NG2:

  • Total Equity: €1,778.6 Mil
  • GF Value™: €10.73 vs. price of €8.40 (21.8% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neogen Business Description

Other Exchanges NEOG:USANG2:Germany
Address 620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score

Get the complete analysis for FRA:NG2

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.40
Price
€10.73
GF Value